Dr Alan Robertson: Ledger

Role	Organisation	Sources
CEO (former)	Pharmaxis	GBS Ventures (2 Nov 2020), GBS Ventures (17 Oct 2011), GBS Ventures (14 Dec 2005), GBS Ventures (23 Aug 2005)

Coverage

Stories naming Dr Alan Robertson. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

2 deals

GBS Ventures completes healthcare fund with global first quartile performance

GBS Ventures announces it has fully wound down its 1998 biotech fund with returns in the top quartile of US peers, recalling portfolio listings, Dynamic Hearing's sale to Wolfson, and its $122.5m fourth fund.

GBS Ventures 17 Oct 2011 GBS Venture Partners Ltd.Amgen Cogstate Dynamic Hearing Genesis Fund Pharmaxis The Australian Bioscience Trust Wolfson Microelectronics Innovation Investment Fund (IIF)Dr Alan Robertson Brigitte Smith Dr Geoff Brooke Dr George Morstyn

News

U.S. Phase III Aridol Trial Enrols First Patient

Pharmaxis announced its Aridol Phase III asthma diagnostic trial has enrolled first patients across 28 US sites, with FDA marketing authorisation planned for 2006.

GBS Ventures 14 Dec 2005 Pharmaxis Dr Alan Robertson

Exit / M&A

Pharmaxis Lists ADRs on NASDAQ

Australian drug developer Pharmaxis has won NASDAQ approval to trade its ADRs under ticker PXSLY, issuing no new shares; SEC registration is expected around 26 August 2005 before trading begins.

GBS Ventures 23 Aug 2005 Nasdaq Pharmaxis US Securities and Exchange Commission Dr Alan Robertson

Also GBS Ventures·GBS Ventures

Dr Alan Robertson

Roles

Coverage

GBS Ventures completes healthcare fund with global first quartile performance

U.S. Phase III Aridol Trial Enrols First Patient

Pharmaxis Lists ADRs on NASDAQ